Overall: Project Summary/Abstract The overall goal of the Alzheimer's Disease (AD) Neuroimaging Initiative
(ADNI) is to discover, standardize, and validate biomarkers for AD treatment trials. Validation is accomplished
by comparing and correlating clinical/cognitive with biomarker data. Impact of ADNI has been to optimize,
standardize and validate biomarkers, especially brain amyloid by PET and CSF measurements of Aß peptides,
termed “Aß amyloid- phenotyping.” There are 907 papers published using ADNI data. We will follow-up with
annual visits, 697 subjects previously enrolled in ADNI2 (cognitively normal controls, subjects currently
enrolled subjects with MCI, and patients with dementia diagnosed as AD) and will enroll 371 new subjects,
while collecting clinical, cognitive, MRI (structural, diffusion, perfusion, resting state), amyloid PET, FDG PET,
cerebrospinal fluid (for a Aß, tau, phosphotau, and other proteins), genetic and autopsy data. In addition
longitudinal measurements of brain tau PET will be performed on all subjects. All data is available without
embargo to from USC/LONI/ADNI. Specific Aims:
1. Longitudinal changes in cognition and associated biomarkers: To determine those measures of
cognition and function, including composite measures, and those biomarker measures which best capture
longitudinal change with highest statistical power to detect treatment effects in clinical trials. Longitudinal
change of brain tau tangles measured with tau PET will be correlated/compared with other measures.
2. Prediction of cognitive decline: To determine the clinical, cognitive, and biomarker measures which best
predict decline of cognition in cognitively normal controls, subjects with MCI, and patients with dementia. In
addition, to determine those biomarkers, especially tau PET, which correlate with cognitive decline.
3. Validation: To validate biomarker measures obtained at baseline and longitudinally by correlating results
with “gold standard” clinical measurements and pathology.
4. Clinical trial design: To determine the optimum outcome measures (especially rate of cognitive decline and
tau PET), predictors of cognitive decline, and inclusion/exclusion criteria for clinical trials of cognitively normal
subjects (for secondary preclinical AD trials) and MCI patients (for prodromal AD trials).
5. Discovery: To determine the effects of other known disease proteins found in AD brains (e.g. alpha-
synuclein, TDP 43,progranulin) and genes, and newly discovered proteins (from proteinomics), genes,and
other analytes (from metabolomics) which provide useful information concerning the pathogenesis/diagnosis of
AD. Discovery is conducted through the add-on studies led/driven by ADNI investigators with oversight by the
NIA and the ADNI Resource Allocation Review Committee (RARC). ADNI methods and data are used in study
design by government and industry funded clinical trials. Continuation of ADNI will help lead to development of
effective treatments which slow progression and prevent AD.